| Pharmacokinetic aspects of retinal drug delivery EM Del Amo, AK Rimpelä, E Heikkinen, OK Kari, E Ramsay, T Lajunen, ... Progress in retinal and eye research 57, 134-185, 2017 | 552 | 2017 |
| Drug transport in corneal epithelium and blood–retina barrier: emerging role of transporters in ocular pharmacokinetics E Mannermaa, KS Vellonen, A Urtti Advanced drug delivery reviews 58 (11), 1136-1163, 2006 | 410 | 2006 |
| Substrates and inhibitors of efflux proteins interfere with the MTT assay in cells and may lead to underestimation of drug toxicity KS Vellonen, P Honkakoski, A Urtti European journal of pharmaceutical sciences 23 (2), 181-188, 2004 | 161 | 2004 |
| Intravitreal clearance and volume of distribution of compounds in rabbits: In silico prediction and pharmacokinetic simulations for drug development EM Del Amo, KS Vellonen, H Kidron, A Urtti European Journal of Pharmaceutics and Biopharmaceutics 95, 215-226, 2015 | 132 | 2015 |
| Paracellular and passive transcellular permeability in immortalized human corneal epithelial cell culture model E Toropainen, VP Ranta, KS Vellonen, J Palmgrén, A Talvitie, M Laavola, ... European journal of pharmaceutical sciences 20 (1), 99-106, 2003 | 102 | 2003 |
| Efflux protein expression in human retinal pigment epithelium cell lines E Mannermaa, KS Vellonen, T Ryhänen, K Kokkonen, VP Ranta, ... Pharmaceutical research 26, 1785-1791, 2009 | 92 | 2009 |
| Filter-cultured ARPE-19 cells as outer blood–retinal barrier model E Mannermaa, M Reinisalo, VP Ranta, KS Vellonen, H Kokki, A Saarikko, ... European journal of pharmaceutical sciences 40 (4), 289-296, 2010 | 81 | 2010 |
| Human corneal cell culture models for drug toxicity studies S Rönkkö, KS Vellonen, K Järvinen, E Toropainen, A Urtti Drug delivery and translational research 6, 660-675, 2016 | 71 | 2016 |
| Effluxing ABC transporters in human corneal epithelium KS Vellonen, E Mannermaa, H Turner, M Häkli, JM Wolosin, T Tervo, ... Journal of pharmaceutical sciences 99 (2), 1087-1098, 2010 | 70 | 2010 |
| Effect of cell differentiation and passage number on the expression of efflux proteins in wild type and vinblastine-induced Caco-2 cell lines S Siissalo, L Laitinen, M Koljonen, KS Vellonen, H Kortejärvi, A Urtti, ... European journal of pharmaceutics and biopharmaceutics 67 (2), 548-554, 2007 | 67 | 2007 |
| An improved cell culture model based on 2/4/A1 cell monolayers for studies of intestinal drug transport: characterization of transport routes S Tavelin, J Taipalensuu, F Hallböök, KS Vellonen, V Moore, P Artursson Pharmaceutical research 20, 373-381, 2003 | 65 | 2003 |
| l-Type Amino Acid Transporter 1 (LAT1/Lat1)-Utilizing Prodrugs Can Improve the Delivery of Drugs into Neurons, Astrocytes and Microglia J Huttunen, S Peltokangas, M Gynther, T Natunen, M Hiltunen, S Auriola, ... Scientific Reports 9 (1), 12860, 2019 | 61 | 2019 |
| Prediction of the corneal permeability of drug-like compounds H Kidron, KS Vellonen, EM Del Amo, A Tissari, A Urtti Pharmaceutical research 27, 1398-1407, 2010 | 59 | 2010 |
| Prediction of ocular drug distribution from systemic blood circulation KS Vellonen, EM Soini, EM Del Amo, A Urtti Molecular pharmaceutics 13 (9), 2906-2911, 2016 | 53 | 2016 |
| A critical assessment of in vitro tissue models for ADME and drug delivery KS Vellonen, M Malinen, E Mannermaa, A Subrizi, E Toropainen, YR Lou, ... Journal of Controlled Release 190, 94-114, 2014 | 53 | 2014 |
| Expression, activity and pharmacokinetic impact of ocular transporters KS Vellonen, L Hellinen, E Mannermaa, M Ruponen, A Urtti, H Kidron Advanced Drug Delivery Reviews 126, 3-22, 2018 | 51 | 2018 |
| Biopharmaceutics of topical ophthalmic suspensions: Importance of viscosity and particle size in ocular absorption of indomethacin E Toropainen, SJ Fraser-Miller, D Novakovic, EM Del Amo, KS Vellonen, ... Pharmaceutics 13 (4), 452, 2021 | 41 | 2021 |
| Ocular Pharmacokinetic Modeling Using Corneal Absorption and Desorption Rates from in Vitro Permeation Experiments with Cultured Corneal Epithelial Cells VP Ranta, M Laavola, E Toropainen, KS Vellonen, A Talvitie, A Urtti Pharmaceutical research 20, 1409-1416, 2003 | 41 | 2003 |
| Prediction of the vitreal half-life of small molecular drug-like compounds H Kidron, EM Del Amo, KS Vellonen, A Urtti Pharmaceutical research 29, 3302-3311, 2012 | 39 | 2012 |
| Alzheimer’s disease phenotype or inflammatory insult does not alter function of L-type amino acid transporter 1 in mouse blood-brain barrier and primary astrocytes M Gynther, E Puris, S Peltokangas, S Auriola, KM Kanninen, J Koistinaho, ... Pharmaceutical research 36, 1-8, 2019 | 38 | 2019 |
